Astal Laboratories adopts FY26 financials at 33rd AGM

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Astal Laboratories Limited held its 33rd AGM on September 29, 2026, via Video Conferencing.
  • Shareholders adopted standalone and consolidated audited financial statements for FY26.
  • Maggidi Venkatesh was re-appointed as Non-Executive Director after retiring by rotation.
  • Thirty-one members participated in the meeting, which concluded at 2:22 pm IST.
powered bylight_fuzz_icon
52233360

*this image is generated using AI for illustrative purposes only.

Astal Laboratories Limited concluded its 33rd Annual General Meeting on September 29, 2026, adopting both standalone and consolidated audited financial statements for the fiscal year ended March 31, 2026. The meeting was conducted entirely through Video Conferencing and Other Audio-Visual Means, ensuring shareholder participation from remote locations.

The proceedings were chaired by Sudheer Karna Kankanala, Whole Time Director, who provided an update on the company's operational and financial activities for FY26. A total of 31 members participated in the virtual meeting, meeting the requisite quorum. The Company Secretary welcomed attendees and confirmed the availability of all statutory registers and reports for electronic inspection during the session.

Key resolutions passed

Shareholders voted on three ordinary business items via the Central Depository Services (India) Limited e-voting portal. The resolutions covered the adoption of financial reports and the re-appointment of a non-executive director retiring by rotation.

Agenda Item Resolution Type Details
Adoption of Standalone Financials Ordinary Audited statements, Board and Auditor reports for FY26
Adoption of Consolidated Financials Ordinary Audited statements, Board and Auditor reports for FY26
Director Re-appointment Ordinary Maggidi Venkatesh, Non-Executive Director, retires by rotation

Governance and attendance

The meeting saw the presence of five directors through the virtual platform, including independent directors Hemachakrapani Bangaraiahgari, Julius Paul Reinhard Paschke, and Radhakishore Pandrangi. Mahendra Prakash Khandelwal, a practicing company secretary, served as the scrutinizer for the e-voting process. The Chairman addressed shareholder queries raised by registered speakers and other participants before concluding the session with a vote of thanks.

Consolidated voting results are scheduled to be disseminated to the stock exchange and published on the company website within 48 hours of the meeting's conclusion.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-0.66%+0.36%-10.41%+2.74%-16.88%0.0%

How does the adoption of the FY26 financial statements reflect on Astal Laboratories' revenue growth and margin trends compared to the previous fiscal year?

What strategic initiatives or capital expenditure plans were highlighted by the Whole Time Director to drive future operational expansion?

How might the re-appointment of Maggidi Venkatesh influence the company's long-term governance strategy and board dynamics?

Astal Laboratories promoter ACESO buys 25,417 shares on BSE

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • ACESO Research Labs LLP bought 25,417 Astal Laboratories shares
  • Transaction valued at ₹19,99,812 executed on BSE
  • Purchase period spanned August 24 to September 8, 2026
  • Promoter holding rose to 2,011,012 equity shares
  • No derivative trading reported by the promoter
powered bylight_fuzz_icon
50667259

*this image is generated using AI for illustrative purposes only.

Astal Laboratories disclosed a share purchase by its promoter, ACESO Research Labs LLP, under SEBI’s insider trading regulations. The transaction reflects increased promoter confidence in the listed entity.

Transaction Details

ACESO Research Labs LLP acquired 25,417 equity shares of Astal Laboratories Limited on the Bombay Stock Exchange (BSE). The purchase was executed in the open market between August 24, 2026 and September 8, 2026. The total value of the transaction stood at ₹19,99,812, excluding taxes and brokerage charges.

The acquisition increased ACESO’s total holding to 2,011,012 equity shares. Prior to this transaction, the promoter held 1,985,595 shares.

Metric Details
Promoter Entity ACESO Research Labs LLP
Shares Purchased 25,417
Transaction Value ₹19,99,812
Execution Window August 24, 2026 – September 8, 2026
Exchange BSE
Post-Transaction Holding 2,011,012 shares

Regulatory Disclosure

The company filed the disclosure with the BSE on September 11, 2026, pursuant to Regulation 7(2)(b) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Mahendra Kumar, Company Secretary and Compliance Officer of Astal Laboratories, signed the intimation letter.

Ravikanti Shailaja, Designated Partner of ACESO Research Labs LLP, submitted Form C to the Board of Directors on September 10, 2026. The form confirmed that no derivatives trading occurred in the company’s securities during this period.

Historical Stock Returns for Astal Laboratories

1 Day5 Days1 Month6 Months1 Year5 Years
-0.66%+0.36%-10.41%+2.74%-16.88%0.0%

Will this open-market purchase signal the start of a larger accumulation phase by ACESO Research Labs LLP in the coming quarters?

How might this increase in promoter holding influence Astal Laboratories' stock liquidity and trading volume on the BSE?

Are there any upcoming operational milestones or financial results that could justify the promoter's increased confidence at this specific time?

More News on Astal Laboratories

1 Year Returns:-16.88%